Pneumococcal Infectious Disease
Conditions
Brief summary
A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.
Detailed description
A phase Ⅲ clinical trial of the study of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd (Sinovac) will be conducted in Chinese pediatric population aged 2 months (minimum 6 weeks)-5 years (before the 6th birthday). The trial is a randomized, double-blind, active controlled study. The objective of this study is to evaluate the immunogenicity and safety of PCV13 manufactured by Sinovac Life Science Co., Ltd. The active control vaccine is Prevenar13®. A total of at least 3080 participants aged 6 weeks to 5 years will be enrolled. Participants will be randomized in 1:1 ratio to the test group or control group.
Interventions
BIOLOGICALSinovac PCV13
One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
BIOLOGICALPrevnar®
One dose of Prevnar® (0.5 mL) is administered intramuscularly.
Sponsors
Sinovac Life Sciences Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Weeks to 5 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy infants or children who are aged 2 months (at least 6 weeks), 7-11 months, 12-23 months and 2-5 years (before the 6th birthday); 2. Participants' guardians provide legal identity document and participants' vaccination record; 3. Participants' guardians understand and voluntarily sign the informed consent form; 4. Participants' guardians can follow all study procedures and stay in contact during the study.
Exclusion criteria
1. Received any pneumococcal vaccine prior to enrollment; 2. History of bacterial pneumonia or invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae, as confirmed by laboratory tests; 3. History of allergy or adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioedema and abdominal pain; 4. History of dystocia, asphyxia rescue and nervous system damage at birth for infants under 2 years of age; 5. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, history of asthma; 6. Autoimmune diseases (such as systemic lupus erythematosus), immunodeficiency diseases or immunosuppressive diseases (such as AIDS, organ transplantation); 7. Severe cardiovascular diseases, diabetes, liver diseases, kidney diseases, malignant tumours. 8. Have/have suffered from a serious neurological disorder (epilepsy or convulsions) or mental illness or have a family history of such diseases. 9. History of thyroidectomy, asplenia, functional asplenia; asplenia or splenectomy caused by any reasons; 10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets level), history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture. 11. Consecutively received ≥14 days of corticosteroid, any other immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or cytotoxic therapy prior to enrollment for infants aged 6 weeks to 2 months or within 6 months prior to enrollment for children aged 7 months to 5 years. 12. Received blood products prior to enrollment for children aged 2 months or within 3 months prior to enrollment for children aged 7 months to 5 years. Receipt of Hepatitis B immunoglobulin one month prior to enrollment is an exception. 13. Received other investigational drugs within 60 days prior to enrollment, or plan to receive such drugs during the study; 14. Received live attenuated vaccine within 14 days prior to enrollment; 15. Received subunit or inactivated or other vaccine within 7 days prior to enrollment; 16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment; 17. Had fever (axillary temperature≥ 37.3 Degree Celsius) before vaccination; 18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml (seropositive rate) | 30 days after primary vaccination | Proportion of serotype-specific IgG concentration ≥0.35 μg/ml |
| Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC) | 30 days after primary vaccination | IgG GMC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml (seropositive rate) | 30 days after booster vaccination | Proportion of serotype-specific IgG concentration ≥0.35 μg/ml |
| Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC) | 30 days after booster vaccination | IgG GMC |
| Proportion of pneumococcal serotype-specific OPA antibody GMT≥1:8 | 30 days after primary vaccination | Proportion of participants with pneumococcal serotype-specific OPA antibody titers ≥ 1:8 |
| Pneumococcal serotype-specific OPA antibody geometric mean titer (GMT) | 30 days after primary vaccination | Pneumococcal serotype-specific OPA antibody GMT |
| Proportion of participants with a pneumococcal serotype-specific IgG concentration ≥ 1.0 μg/mL | 30 days after primary vaccination | Proportion of participants with a pneumococcal serotype-specific IgG concentration ≥ 1.0 μg/mL |
| Pneumococcal serotype-specific IgG antibody geometric mean increase (GMI) | 30 days after primary vaccination | Pneumococcal serotype-specific IgG GMI |
| Pneumococcal serotype-specific OPA antibody geometric mean increase(GMI) | 30 days after primary vaccination | Pneumococcal serotype-specific OPA antibody GMI |
| Proportion of participants with pneumococcal serotype-specific OPA titers ≥ 1:8 (seropositive rate) | 30 days after booster vaccination | Proportion of participants with pneumococcal serotype-specific OPA titers ≥ 1:8 (seropositive rate) |
| Safety of Sinovac PCV13 | 0-30 days within each dose | Incidence of adverse reactions |
Countries
China
Contacts
CONTACTYanxia Wang
CONTACTXiaoqiang Liu
PRINCIPAL_INVESTIGATORYanxia Wang
Henan Provincial Center for Disease Control and Prevention
Outcome results
None listed